.Nature Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after an average follow-up of 11 months, individuals along with metastatic stomach growths who got biomarker-matched therapies based on spreading tumor DNA profiling presented a more significant professional perk than those getting unequaled therapy.